This Is MS Multiple Sclerosis Knowledge & Support Community

1st Venous Endovascular Forum in Katowice

http://www.vefconference.pl/

the website lists the speakers, which seems to contain some great CCSVI minds aswell as some neuros, the feedback should be very interesting.

Yes, look what's coming ahead in Europe:


VEF Conference, Poland, March 3 and 4

March 3:

14:00-17:30 CCSVI Diagnostic workshops:
MRI equipment preparation in order to perform MRI diagnostic tests.
Doppler Ultrasound equipment preparation and Doppler USG examination training
19:00-23:00 Welcome Reception.
March 4:

09:00-09:10 What do we know and do not know about CCSVI?

(Assoc. Prof. Marian Simka, MD, PhD, Poland)
09:10-09:30 Fighting for Treatment of CCSVI in Canada: Untangling Science and Politics.

(Kirsty Duncan, MD, PhD, Canada)
09:30-09:50 Imaging as a Treatment Planning Tool for CCSVI.

(Prof. E. Mark Haacke, MD, PhD, USA)
09:50-10:30 Neurological panel
Controversy on the prevalence of CCSVI in MS.

(Prof. Danuta Ryglewicz, MD, PhD, Poland)
Clinical picture and up-today diagnostic of MS.

(Prof. Jerzy Kotowicz, MD, PhD, Poland)
What we should assess doing follow-up in MS patients.

(Jacek Zaborski, MD, PhD, Poland)
Current concepts in MS pathogenesis.

(Assoc. Prof. Konrad Rejdak, MD, PhD, Poland)
Ultrasound examination of cerebral venous hemodynamics.

(Joanna Wojczal, MD, PhD, Poland)
10:50-11:00 Angiographic findings of CCSVI: Characterization of venous lesions in CCSVI and review of angiographic findings of CCSVI.

(Ma'moon Hasan Al-Omari, MD, PhD, Jordan)
11:00-11:10 Early and mid term results of Endovascular treatment in patients with CCSVI and MS. Experience in Tokuda Hospital.

(Assoc. Prof. Ivo Petrov, MD, PhD, Bulgaria)
11:10-11:20 How we treat CCSVI in India.

(Vikas Gupta, MD, PhD, India)
11:20-11:30 CCSVI in Argentina. Argenmedic - our working progress.

(Prof. Cristian Schulte, MD, PhD, Argentina)
11:30-11:40 How we treat CCSVI in UK.

(Thomas Cormac Gilhooly, MD, PhD, United Kingdom)
11:40-11:50 Improvement of chronic fatigue after the treatment for CCSVI.

(Prof. Miro Denišlič, MD, PhD, Slovenia)
11:50-12:00 Results of the world survey on diagnostics and interventions for CCSVI.

(Assoc. Prof. Marian Simka, MD, PhD, Poland)
12:00-12:40 Discussion panel.
12:40-13:30 Live case I-transmission of the CCSVI treatment from Euromedic Clinic.
14:30-14:45 Presentation of problems, complications and difficulties encountered during CCSVI endovascular procedure..

(Tomasz Ludyga, MD, PhD, Poland)
14:45-15:00 Thrombosis and intimal hyperplasia following endovascular treatments for CCSVI: which prophylaxis could be the best one?

(Assoc. Prof. Tomasz Urbanek, MD, PhD, Poland)
15:00-15:50 Live case II- transmission of the CCSVI treatment from Euromedic Clinic..
15:50-16:00 Ophthalmological findings..

(Aneta Adamczyk-Ludyga, MD, PhD, Poland)
16:00-16:10 Does venous pathology play a role in the pathogenesis of multiple sclerosis?

(Assoc. Prof. Marian Simka, MD, PhD, Poland)
16:30-16:40 Blood gas analysis in patients with Chronic Cerebro-spinal Venous Insufficiency

(Prof. Lachezar Grozdinski, MD, PhD, Bulgaria)
16:40-16:50 Venous hypertension in the central nervous system - a symptom or disease entity?

(Prof. Krzysztof Ziaja, MD, PhD, Poland)
16:50-17:00 Changes in physical, mental and neurological status in MS patients six months after endovascular procedure.

(Jacek Kostecki, MD, PhD, Poland)
17:00-17:10 How to improve the results and avoid problems: what have we learnt during last year.

(Tomasz Ludyga, MD, PhD, Poland)
17:10-18:00 "Round table" discussion – summary of:
Formal and medical guidelines for further action
New areas of application of balloon angioplasty and stenting; Parkinson disease?, Sclerosis lateralis amyotrophica? Alzheimer disease?
Multicentre research
New materials (stents, balloons)
Implement the CCSVI procedure as a universally available treatment
18:00-18:15 The Conference Closing Ceremony.
20:30-02:00 Silesian night – dinner and concert in Monopol Hotel, Katowice

Prof. Simka's speach: http://tinyurl.com/4sgx3ru
Erika

Erika, great find! This is a whole pdf of his presentation:

WHAT DO WE KNOW AND DO
NOT KNOW ABOUT CCSVI?

Marian Simka

What we do not know:

• Is CCSVI the causal factor for MS, a co-factor or an
epiphenomenon
...

I understand what it would mean if CCVSI is causal, I think co-factor means there are more than one factors causing MS but CCSVI would be included in them, and epiphenomon must mean CCSVI would be caused by the MS?? I am guessing on that last one.

Are we undertreating or overtreating the
patients ?

I've made this point here myself, I agree, this is not yet known and it needs to be worked out. This is one of the reasons I am as big a fan as I am of IVUS, it takes some of the guesswork out of what the IRs are doing because they can see more clearly, if they know what they are looking for on IVUS.

He has a bunch of points, all very good, this is an easy read and worth the reading.

• Are treatments for CCSVI efficient in a long-
term perspective ?
• Which subgroups of the patients can benefit
and which cannot ?

I think every subgroup will benefit from increases in CNS oxygenation. It's all in how benefit is defined.

Here too is Dr. Ludyga's presentation on opthalmological findings and optical coherence tomography!

<shortened url>

220 MS patients were performed catheter
venography to diagnose and evaluate CCSVI and OCT
( GCC AVG, GCC FLV, GCC GLV and RNFL AVG )

• Ocular pathologies were found more often in the
cases of:
- CCSVI limited to only one internal jugular vein,
especially in the cases of severe outflow blockage of
this vein
- asymetric blockages of internal jugular veins

• Venous anomalies of the azygous vein were not
associated with higher risk of ocular pathology.

• MS patients who were not diagnosed with CCSVI
showed exceptionally high prevalence of OCT
abnormalities.

High percentages of retinal pathologies in
non-CCSVI patients indicate that the
mechanism of retinal neurodegeneration in
MS is far more complex and cannot be
expained as an obvious vascular pathology

some of my questions --
* Are there MS patients who do not have CCSVI? (I do not think this has been answered yet.) (Misdiagnosis of MS would be excluded.)
* Why would ocular pathologies be more common if only one jugular is occluded compared to if both jugulars are occluded? How odd.

VEF Conference TV report

Erika

• Please find dr Aneta Adamczyk-Ludyga VEF presentation clicking the link below.

<shortened url>

(You can use this presentation under the terms of the license - http://crea...tivecommons.org/licenses/by-sa/3.0/)

• Please find one of dr Simka VEF presentations clicking the link below.

<shortened url>

(You can use this presentation under the terms of the license - http://creativecommons.org/licenses/by-sa/3.0/)
[/b]

great links!

...........